# Propafenone

Drug · id `cardio:propafenone` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Rythmol

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

Propafenone is a medicine taken by mouth, sold as propafenone hydrochloride, that the US label describes as an antiarrhythmic drug, a medicine for heart rhythm problems. The label read, a generic tablet label, lists three uses: to prolong the time to recurrence of paroxysmal atrial fibrillation or flutter that causes disabling symptoms, and of paroxysmal supraventricular tachycardia that causes disabling symptoms, in patients without structural heart disease; and to treat documented ventricular arrhythmias, such as sustained ventricular tachycardia, that a physician judges to be life-threatening. The label says the effect of propafenone on mortality has not been determined. It carries a boxed warning on mortality.

## Technical summary

RxNorm ingredient 8754 (propafenone); the label names the salt propafenone hydrochloride (RxNorm 203135, UNII 33XCH0HOCD, a broad match to the ingredient). MeSH descriptor D011405 is Propafenone. RxClass lists the FDA established pharmacologic class Antiarrhythmic. The label read is the ANI Pharmaceuticals, Inc. generic propafenone hydrochloride tablet label, application ANDA076550, effective 2025-09-12 in openFDA; propafenone hydrochloride is the only active ingredient. The brands Rythmol (NDA019151) and Rythmol SR (NDA021416) are listed in Drugs@FDA with marketing status Discontinued, and the openFDA name search for Rythmol returned no record. The extended-release capsule labels, whose indication is limited to symptomatic atrial fibrillation, were not used, and neither were the other openFDA propafenone labels. This page records label indications, the class, the mechanism sentence and the boxed warning on mortality only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients with structural heart disease, and the population of the trial known as Cardiac Arrhythmia Suppression Trial (CAST), as described in a US propafenone label boxed warning

Recipient: Recipient not specified; Population: The warning speaks of subjects with asymptomatic non-life-threatening ventricular arrhythmias after a myocardial infarction (the trial it cites, treated with encainide or flecainide) and of patients with structural heart disease (for any IC antiarrhythmic). The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label carries a boxed warning titled mortality. It says that in the trial known as Cardiac Arrhythmia Suppression Trial (CAST) an increased rate of death or reversed cardiac arrest was seen in subjects treated with encainide or flecainide (Class IC antiarrhythmics) compared with placebo, and that it is prudent to consider any IC antiarrhythmic to have a significant proarrhythmic risk when structural heart disease is present.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: The warning speaks of subjects with asymptomatic non-life-threatening ventricular arrhythmias after a myocardial infarction (the trial it cites, treated with encainide or flecainide) and of patients with structural heart disease (for any IC antiarrhythmic). The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the title and two statements of the label's boxed warning only. The CAST result was in patients treated with encainide or flecainide, not propafenone; the warning says its applicability to other drugs and populations is uncertain. The trial numbers and the warning's statement on non-life-threatening ventricular arrhythmias are not repeated. Other warnings, contraindications and interactions were not recorded, and no instruction is given. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for propafenone hydrochloride tablets, ANI Pharmaceuticals, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 8d1be333-be2b-4064-86a4-c2ad9ad07b83 (manufacturer ANI Pharmaceuticals, Inc., application ANDA076550), returned on 2026-11-18. The label text is dated 2025-09-12 (effective\_time). Other openFDA records of propafenone labels (tablets and extended-release capsules) from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228d1be333-be2b-4064-86a4-c2ad9ad07b83%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], title. Retrieved 2026-11-18T21:55:09Z. Source state: Current. Version fingerprint: f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d.
     How it applies: Label passage quoted in the research quote table (LB-11).
  2. Supports: openFDA drug label record for propafenone hydrochloride tablets, ANI Pharmaceuticals, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 8d1be333-be2b-4064-86a4-c2ad9ad07b83 (manufacturer ANI Pharmaceuticals, Inc., application ANDA076550), returned on 2026-11-18. The label text is dated 2025-09-12 (effective\_time). Other openFDA records of propafenone labels (tablets and extended-release capsules) from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228d1be333-be2b-4064-86a4-c2ad9ad07b83%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], first bullet. Retrieved 2026-11-18T21:55:09Z. Source state: Current. Version fingerprint: f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d.
     How it applies: Label passage quoted in the research quote table (LB-12).
  3. Supports: openFDA drug label record for propafenone hydrochloride tablets, ANI Pharmaceuticals, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 8d1be333-be2b-4064-86a4-c2ad9ad07b83 (manufacturer ANI Pharmaceuticals, Inc., application ANDA076550), returned on 2026-11-18. The label text is dated 2025-09-12 (effective\_time). Other openFDA records of propafenone labels (tablets and extended-release capsules) from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228d1be333-be2b-4064-86a4-c2ad9ad07b83%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], second bullet. Retrieved 2026-11-18T21:55:09Z. Source state: Current. Version fingerprint: f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d.
     How it applies: Label passage quoted in the research quote table (LB-13).
  4. Background: openFDA drug label record for propafenone hydrochloride tablets, ANI Pharmaceuticals, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 8d1be333-be2b-4064-86a4-c2ad9ad07b83 (manufacturer ANI Pharmaceuticals, Inc., application ANDA076550), returned on 2026-11-18. The label text is dated 2025-09-12 (effective\_time). Other openFDA records of propafenone labels (tablets and extended-release capsules) from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228d1be333-be2b-4064-86a4-c2ad9ad07b83%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T21:55:09Z. Source state: Current. Version fingerprint: f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d.
     How it applies: Effective date of the label text read, 20250912.

## Context: Patients with paroxysmal atrial fibrillation or flutter, paroxysmal supraventricular tachycardia, or life-threatening ventricular arrhythmias, as described in the US label of propafenone hydrochloride tablets

Recipient: Recipient not specified; Population: Patients described in the indications section of the label: patients without structural heart disease who have paroxysmal atrial fibrillation or flutter, or paroxysmal supraventricular tachycardia, with disabling symptoms, and patients with documented life-threatening ventricular arrhythmias. The passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of propafenone hydrochloride tablets (ANI Pharmaceuticals, Inc., application ANDA076550; the version dated 2025-09-12 in openFDA) describes propafenone as an antiarrhythmic. It lists prolonging the time to recurrence of paroxysmal atrial fibrillation or flutter, and of paroxysmal supraventricular tachycardia, each associated with disabling symptoms in patients without structural heart disease, and treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. It states that the effect of propafenone on mortality has not been determined.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label: patients without structural heart disease who have paroxysmal atrial fibrillation or flutter, or paroxysmal supraventricular tachycardia, with disabling symptoms, and patients with documented life-threatening ventricular arrhythmias. The passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US generic tablet label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists usage considerations (for example, that use in permanent atrial fibrillation has not been evaluated); those are the label's statements and are not repeated as advice. Extended-release capsule labels, which state a narrower atrial fibrillation indication, were not read. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. openFDA lists other propafenone labels with different dates, and its own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for propafenone hydrochloride tablets, ANI Pharmaceuticals, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 8d1be333-be2b-4064-86a4-c2ad9ad07b83 (manufacturer ANI Pharmaceuticals, Inc., application ANDA076550), returned on 2026-11-18. The label text is dated 2025-09-12 (effective\_time). Other openFDA records of propafenone labels (tablets and extended-release capsules) from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228d1be333-be2b-4064-86a4-c2ad9ad07b83%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], Highlights statement. Retrieved 2026-11-18T21:55:09Z. Source state: Current. Version fingerprint: f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for propafenone hydrochloride tablets, ANI Pharmaceuticals, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 8d1be333-be2b-4064-86a4-c2ad9ad07b83 (manufacturer ANI Pharmaceuticals, Inc., application ANDA076550), returned on 2026-11-18. The label text is dated 2025-09-12 (effective\_time). Other openFDA records of propafenone labels (tablets and extended-release capsules) from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228d1be333-be2b-4064-86a4-c2ad9ad07b83%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], indications statement. Retrieved 2026-11-18T21:55:09Z. Source state: Current. Version fingerprint: f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d.
     How it applies: Label passage quoted in the research quote table (LB-05).
  3. Supports: openFDA drug label record for propafenone hydrochloride tablets, ANI Pharmaceuticals, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 8d1be333-be2b-4064-86a4-c2ad9ad07b83 (manufacturer ANI Pharmaceuticals, Inc., application ANDA076550), returned on 2026-11-18. The label text is dated 2025-09-12 (effective\_time). Other openFDA records of propafenone labels (tablets and extended-release capsules) from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228d1be333-be2b-4064-86a4-c2ad9ad07b83%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], first bullet. Retrieved 2026-11-18T21:55:09Z. Source state: Current. Version fingerprint: f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d.
     How it applies: Label passage quoted in the research quote table (LB-06).
  4. Supports: openFDA drug label record for propafenone hydrochloride tablets, ANI Pharmaceuticals, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 8d1be333-be2b-4064-86a4-c2ad9ad07b83 (manufacturer ANI Pharmaceuticals, Inc., application ANDA076550), returned on 2026-11-18. The label text is dated 2025-09-12 (effective\_time). Other openFDA records of propafenone labels (tablets and extended-release capsules) from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228d1be333-be2b-4064-86a4-c2ad9ad07b83%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], second bullet. Retrieved 2026-11-18T21:55:09Z. Source state: Current. Version fingerprint: f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d.
     How it applies: Label passage quoted in the research quote table (LB-07).
  5. Supports: openFDA drug label record for propafenone hydrochloride tablets, ANI Pharmaceuticals, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 8d1be333-be2b-4064-86a4-c2ad9ad07b83 (manufacturer ANI Pharmaceuticals, Inc., application ANDA076550), returned on 2026-11-18. The label text is dated 2025-09-12 (effective\_time). Other openFDA records of propafenone labels (tablets and extended-release capsules) from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228d1be333-be2b-4064-86a4-c2ad9ad07b83%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], third bullet. Retrieved 2026-11-18T21:55:09Z. Source state: Current. Version fingerprint: f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d.
     How it applies: Label passage quoted in the research quote table (LB-08).
  6. Supports: openFDA drug label record for propafenone hydrochloride tablets, ANI Pharmaceuticals, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 8d1be333-be2b-4064-86a4-c2ad9ad07b83 (manufacturer ANI Pharmaceuticals, Inc., application ANDA076550), returned on 2026-11-18. The label text is dated 2025-09-12 (effective\_time). Other openFDA records of propafenone labels (tablets and extended-release capsules) from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228d1be333-be2b-4064-86a4-c2ad9ad07b83%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], usage considerations. Retrieved 2026-11-18T21:55:09Z. Source state: Current. Version fingerprint: f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d.
     How it applies: Label passage quoted in the research quote table (LB-09).
  7. Background: openFDA drug label record for propafenone hydrochloride tablets, ANI Pharmaceuticals, Inc. label: indications, class, boxed warning (Regulator, edition The openFDA drug label record for set id 8d1be333-be2b-4064-86a4-c2ad9ad07b83 (manufacturer ANI Pharmaceuticals, Inc., application ANDA076550), returned on 2026-11-18. The label text is dated 2025-09-12 (effective\_time). Other openFDA records of propafenone labels (tablets and extended-release capsules) from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%228d1be333-be2b-4064-86a4-c2ad9ad07b83%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T21:55:09Z. Source state: Current. Version fingerprint: f5314b4941e7937612a4798d433c561a8dc9396a491e4f825c700804c5905e9d.
     How it applies: Effective date of the label text read, 20250912.

## Connected pages

- Propafenone is an antiarrhythmic (FDA established pharmacologic class in RxClass): Antiarrhythmic drugs (`cardio:antiarrhythmic-drugs`)
- FDA label lists prolonging the time to recurrence of paroxysmal atrial fibrillation or flutter associated with disabling symptoms, in patients without structural heart disease, as an indication: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`) [a claim, not a settled fact; see claim `cardio:claim-fda-propafenone-label-indications` and its context]
- FDA label lists prolonging the time to recurrence of paroxysmal atrial fibrillation or flutter associated with disabling symptoms, in patients without structural heart disease, as an indication: Atrial flutter (`cardio:atrial-flutter`) [a claim, not a settled fact; see claim `cardio:claim-fda-propafenone-label-indications` and its context]
- FDA label lists prolonging the time to recurrence of paroxysmal supraventricular tachycardia associated with disabling symptoms, in patients without structural heart disease, as an indication: Supraventricular tachycardia (`cardio:supraventricular-tachycardia`) [a claim, not a settled fact; see claim `cardio:claim-fda-propafenone-label-indications` and its context]
- FDA label lists treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, as an indication: Ventricular tachycardia (`cardio:ventricular-tachycardia`) [a claim, not a settled fact; see claim `cardio:claim-fda-propafenone-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: c87c3a7d3e40ae10b91135bb12aa7c3a7d86a70002c2787e555b7e7309ef9dd5
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
